Genmab and Janssen's Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receive the US FDA's Approval to Treat Multiple Myeloma in Adults
Shots:
- The approval is based on two studies: COLUMBA (MMY3012- P-III) study and P-II PLEIADES (MMY2040) study- which involves assessing of subcutaneous daratumumab (1800 mg) with rHuPH20 2-000 U/mL- combination with either bortezomib- lenalidomide and dexamethasone (D-VRd) or bortezomib- melphalan and prednisone (D-VMP)
- In Feb 2019- results from COLUMBA study were announced- presented in oral sessions at the 2019 ASCO Annual Meeting and the 24th European Hematology Association (EHA) Annual Congress. Additionally- in Dec 2019- an update of the COLUMBA data as well as data from the PLEIADES study were presented during poster sessions at the 61st ASH Annual Meeting
- DARZALEX FASPRO is a fixed dose formulation administered every three to five minutes to patients with multiple myeloma in the US
Click here to read full press release/ article
Ref: Globenewswire | Image: Janssen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com